Gene-Fixed skin patches tested for rare 'Butterfly' disease
NCT ID NCT04186650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new approach for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that causes fragile, blistering skin. Researchers take a small piece of the patient's own skin, fix the faulty gene in a lab, grow it into a larger sheet, and graft it back onto wounds. The study involves 3 adults and focuses on safety and whether the graft helps the skin produce the missing protein.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- COL7A1 gene-corrected skin graft
- What this could lead to
- If successful, this could provide a way to heal large skin wounds in people with RDEB by restoring a missing protein, potentially reducing pain and infection risk.
- What could go wrong
- This is a very early, small trial with only 3 participants, so results may not apply to everyone. Risks include graft failure, immune reactions, or long-term side effects from the gene therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 3 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2020
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Clinical and molecular diagnosis of RDEB with confirmed bi-allelic COL7A1 mutations 2. Reduced staining of C7 on skin biopsy, measured by immunofluorescence microscopy (IF) 3. A reduced number of/or morphologically abnormal anchoring fibrils confirmed by TEM 4. Detection of non-collagenous-1 domain (NC-1) of C7 on skin biopsy, measured by immunofluorescence microscopy (IF) and/or Western blot (WB) analysis 5. Presence of ≥100cm2 of blistered and/or erosive skin areas including chronic wounds suitable for skin grafting 6. Ability to undergo anaesthesia for skin grafting procedures 7. Subjects aged 18 years, willing and able to give informed consent Exclusion Criteria: 1. Recipients of other investigational medicinal products within 6 months prior to enrolment into this study 2. Past medical history of biopsy proven skin malignancy 3. Immunotherapy including oral corticosteroids (Prednisolone \>1mg/kg) for more than one week (intranasal and topical preparations are permitted) or chemotherapy within 60 days of enrolment into this study 4. Known allergy to any of the constituents of the investigational medicinal product (IMP) including Penicillin 5. Subjects with BOTH: * positive serum antibodies to C7 confirmed by ELISA and * positive IIF with binding to the base of salt split skin and/or * positive Western blot 6. Positive results for HIV, Hepatitis BsAg, Hepatitis BcAb, Hepatitis C IgG, HTLV1\&2 or Syphilis serology 7. Clinically significant medical, psychological or laboratory abnormalities limiting the ability of the subject to travel to the trial site(s) and to undergo grafting and follow-up procedures, as determined by the Investigator 8. Absence of adequate social support 9. Subjects who are pregnant, breast-feeding or of child-bearing potential who are neither abstinent nor practicing an acceptable means of contraception when this is in line with the usual and preferred lifestyle of the subject, as determined by the Investigator, for the duration of the trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Epidermolysis bullosa dystrophica, recessive are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Imagine Necker Hospital
Paris, 75743, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.